Duvelisib - CAS 1201438-56-3
Catalog number: B0084-462545
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C22H17ClN6O
Molecular Weight:
416.869
COA:
Inquire
Targets:
PI3K
Description:
Duvelisib, also known as IPI-145 and INK-1197, is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, PI3K delta/gamma inhibitor IPI 145 prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal, non-neoplastic cells is minimally or not affected which would result in a more favorable side effect profile.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-462545 100 mg $228 In stock
Bulk Inquiry
Appearance:
white solid powder
Synonyms:
IPI145; IPI 145; IPI-145. INK-1197; INK 1197; INK1197; Duvelisib.
MSDS:
Inquire
Application:
For research used only
InChIKey:
SJVQHLPISAIATJ-ZDUSSCGKSA-N
InChI:
InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1
Canonical SMILES:
CC(C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
Current Developer:
Infinity Pharmaceuticals, Inc. and Intellikine
1.The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
Balakrishnan K1,2, Peluso M3, Fu M2, Rosin NY2, Burger JA2, Wierda WG2, Keating MJ2, Faia K3, O'Brien S2, Kutok JL3, Gandhi V1,2. Leukemia. 2015 Sep;29(9):1811-22. doi: 10.1038/leu.2015.105. Epub 2015 Apr 28.
The functional relevance of the B-cell receptor (BCR) and the evolution of protein kinases as therapeutic targets have recently shifted the paradigm for treatment of B-cell malignancies. Inhibition of p110δ with idelalisib has shown clinical activity in chronic lymphocytic leukemia (CLL). The dynamic interplay of isoforms p110δ and p110γ in leukocytes support the hypothesis that dual blockade may provide a therapeutic benefit. IPI-145, an oral inhibitor of p110δ and p110γ isoforms, sensitizes BCR-stimulated and/or stromal co-cultured primary CLL cells to apoptosis (median 20%, n=57; P<0.0001) including samples with poor prognostic markers, unmutated IgVH (n=28) and prior treatment (n=15; P<0.0001). IPI-145 potently inhibits the CD40L/IL-2/IL-10 induced proliferation of CLL cells with an IC50 in sub-nanomolar range. A corresponding dose-responsive inhibition of pAKT(Ser473) is observed with an IC50 of 0.36 nM. IPI-145 diminishes the BCR-induced chemokines CCL3 and CCL4 secretion to 17% and 37%, respectively.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PI3K Products


CAS 677338-12-4 PIK-90

PIK-90
(CAS: 677338-12-4)

PIK-90 is a potent PI3K inhibitor.

CAS 1013098-90-2 PI3Kα/mTOR-IN-1

PI3Kα/mTOR-IN-1
(CAS: 1013098-90-2)

PI3Kα/mTOR-IN-1 is a potent dual inhibitor of PI3Kα/mTOR (Kis= 10.6 nM and 12.5 nM for mTOR and PI3Kα, respectively).

CAS 1383716-46-8 VPS34 inhibitor 1

VPS34 inhibitor 1
(CAS: 1383716-46-8)

VPS34 inhibitor 1 is a potent and selective inhibitor of VPS34 (IC50= 15 nM). Vps34 is a phosphoinositide 3-kinase (PI3K) class III isoform that has attracted m...

CAS 1276105-89-5 CNX-1351

CNX-1351
(CAS: 1276105-89-5)

CNX-1351 is a selective covalent Inhibitor of PI3Kα. In an end point assay, CNX-1351 potently inhibited PI3Kα and was 20−400 times less potent against β, γ, an...

CAS 1276553-09-3 PF-4989216

PF-4989216
(CAS: 1276553-09-3)

PF-4989216 is a novel potent and selective PI3K inhibitor. PF-4989216 inhibits the phosphorylation of PI3K downstream molecules and subsequently leads to inhib...

CAS 1312445-63-8 NVP-BKM120 Hydrochloride

NVP-BKM120 Hydrochloride
(CAS: 1312445-63-8)

NVP-BKM120 Hcl(BKM120) is a selective PI3K inhibitor of p110&alpha;/&beta;/&delta;/&gamma; with IC50 of 52 nM/166 nM/116 nM/262 nM, respectively.

CAS 2060571-02-8 GDC-0077

GDC-0077
(CAS: 2060571-02-8)

GDC-0077 is an orally available and selective PI3K inhibitor (IC50 = 0.038 + 0.003 nM) with > 300-fold selective over other Class I PI3K isoforms. GDC-0077 exer...

CAS 934529-30-3 XL PI3K/mTOR inhibitor

XL PI3K/mTOR inhibitor
(CAS: 934529-30-3)

An orally bioactive PI3K/mTOR tyrosine kinase inhibitor.

PDK1 inhibitor 2610

PDK1 inhibitor 2610 is an ATP-competitive and selective dual PI3K and PDPK1 inhibitor (IC50 values 34 nM and 94 nM for PDK1 and p-T308-PKB, respectively).

CAS 372196-77-5 PIK 75 hydrochloride

PIK 75 hydrochloride
(CAS: 372196-77-5)

PIK-75 is a p110α inhibitor with IC50 of 5.8 nM (200-fold more potently than p110β), isoform-specific mutants at Ser773, and also potently inhibits DNA-PK with ...

AM-9635
(CAS: 1338483-10-5)

AM-9635 is a selective Phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor. AM-9635 exhibits good cellular potency (in vitro pAKT IC50 = 4.2 nM ). AM-9635 can...

CAS 1702816-75-8 PI3Kδ-IN-2

PI3Kδ-IN-2
(CAS: 1702816-75-8)

PI3Kδ-IN-2 is a potent and selective inhibitor ofPI3Kδ (IC50= 6.4 M).

CAS 1252594-99-2 ETP-46321

ETP-46321
(CAS: 1252594-99-2)

ETP-46321 is a potent and orally bioavailable PI3K α, δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after o...

CAS 1198357-79-7 ETP 45658

ETP 45658
(CAS: 1198357-79-7)

ETP 45658 is a PI 3-kinase inhibitor (IC50 = 22, 30, 129 and 710 nM for PI 3-Kα, PI 3-Kδ, PI 3-Kβ and PI 3-Kγ, respectively), and it also inhibits DNA-PK and mT...

Duvelisib R enantiomer
(CAS: 1261590-48-0)

The R isomer analogue of Duvelisib which is a high selective PI3K δ/γ inhibitor.

CAS 1676893-24-5 NSC781406

NSC781406
(CAS: 1676893-24-5)

NSC781406 demonstrates potent PI3K inhibition (PI3Kα IC50=2.0 nM) and is a highly potent mTOR inhibitor, with reasonable liver microsome stability.

CAS 944396-07-0 BKM120

BKM120
(CAS: 944396-07-0)

BKM120, also called as buparlisib or NVP-BKM120, activity in a range of preclinical cancermodels, specifically inhbits class I PI3K isoforms, which blocks p110α...

CAS 1236188-16-1 740 Y-P

740 Y-P
(CAS: 1236188-16-1)

740 Y-P is a cell-permeable phosphopeptide activator of PI3K. It binds to the p85 N- and C-terminal SH2 domains of PI3K but not to GST or the N-terminal domain ...

AM-8508
(CAS: 1338483-67-2)

AM-8508 is a selective Phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor. AM-8508 exhibits good cellular potency (in vitro pAKT IC50 = 4.6 nM ) and excellen...

CAS 371242-69-2 IC-87114

IC-87114
(CAS: 371242-69-2)

IC-87114 is a potent and selective PI3Kδ inhibitor with IC50 of 0.5 μM.

Chemical Structure

CAS 1201438-56-3 Duvelisib

Quick Inquiry

Verification code

Featured Items